

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: pF719105-FY4

Catalog 11800

Number:

Lot Number: 100161

Release Α Category:

Provided: 10 µg of dried purified DNA stabilized in DNAstable Plus

Cloning Vector: See pNL4.3 GenBank accession AF324493.1 for the vector sequence. The vector contains

an AmpR marker.

Restriction maps match those of pNL4.3 with the exception of a novel Bal I site at **Cloning Site:**

nucleotide position 4552 and PfIM 1 site at nucleotide position 5302 that were removed and a PfIM 1 site added at nucleotide position 3491. The unique Apa I site upstream of protease at nucleotide position 2009 is used as a 5' restriction site; double-digestion with Apa I/Bal

I generates a protease-deleted linearized vector. Inserts are amplified from clinically-derived viral cDNA using Pfu; Purified PCR products are digested and ligated into the vector using cycling T4 ligation, and the ligation product is grown in Stbl3 E. coli in LB+carbenicillin, then plated and sequenced. The cloned region contains the entire protease open reading frame; the flanking regions cloned along with protease include 3'

end of gag with the gag cleavage site, and the 5' end of RT.

GenBank: KC109813

Host Strain: Stbl3 E coli for DNA and C8166/Sup T1 cell supernatant for Virus stock.

Description: This clone (clone F719105-FY4, PtID 38129) is part of a panel containing each of the

canonical protease inhibitor-resistance pathways in clinically derived HIV-1 clones. In contrast to site-directed mutants, the mutations are present in their naturally occurring genetic contexts, which may include known accessory drug-resistance mutations, as well as changes at positions that are not currently known to be associated with drug resistance. As the clones are also infectious and replication-competent, they can be used for in vitro susceptibility testing of new protease inhibitors (PIs). PIs that are active against these

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/17/2018 Page 1 of 2 ciones are likely to retain activity against the most clinically relevant, or possibly all, protease inhibitor-resistant variants. Researchers can also create their own recombinant viruses using the pNLPFB vector. A protocol is available upon request (please contact Shafer Lab)

Please see this <u>TABLE</u> for the other clones in this panel.

Special

This reagent is currently being provided as dried purified DNA stabilized in DNAstable Plus. Characteristics: Please see the notice for additional information and the protocol for reconstitution of dried

DNA reagents. Dried DNA Notice

Recommended Storage:

Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier

Contributor: Robert Shafer

References: Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of

Human Immunodeficiency Virus Type 1 Vici Varghese, Yumi Mitsuya, W. Jeffrey Fessel, Tommy F. Liu, George L. Melikian, a David A. Katzenstein, Celia A. Schiffer, Susan P. Holmes, and Robert W. Shafer. Antimicrob Agents Chemother. 2013 September; 57(9):

4290-4299. doi: 10.1128/AAC.00614-13. PMID: 23796938.

Acknowledgment for publications should read "The following reagent was obtained through NOTE:

the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr Robert Shafer: Cat#

11800, pF719105-FY4" Also include the reference cited above in any publications.

December 17, 2018 Last Updated:

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/17/2018 Page 2 of 2